- Markets
- Healthcare
- BERLDRG
BERLDRG
New to Zerodha? Sign-up for free.
New to Zerodha? Sign-up for free.
-
Share Price
-
Financials
-
Revenue mix
-
Shareholdings
-
Peers
-
Forensics
- 5D
- 1M
- 6M
- YTD
- 1Y
- 5Y
- MAX
This data is currently unavailable for this company.
-
Summary
-
Profit & Loss
-
Balance sheet
-
Cashflow
This data is currently unavailable for this company.
(In Cr.) |
---|
(In Cr.) | ||||
---|---|---|---|---|
This data is currently unavailable for this company. |
(In %) |
---|
(In Cr.) |
---|
Financial Year (In Cr.) |
---|
-
Product wise
-
Location wise
Revenue Mix
This data is currently unavailable for this company.
Revenue Mix
This data is currently unavailable for this company.
Recent events
-
News
-
Corporate Actions
This data is currently unavailable for this company.
Events:
More Micro Cap Ideas
See similar 'Micro' cap companies with recent activity
Promoter Buying
Companies where the promoters are bullish
Capex
Companies investing on expansion
Superstar Investor
Companies where well known investors have invested
Popular questions
-
Business
-
Financials
-
Share Price
-
Shareholdings
What does Beryl Drugs do?
Beryl Drugs Limited, established in 1993, specializes in pharmaceutical manufacturing with a global presence offering research, development, contract manufacturing, and veterinary products.
Who are the competitors of Beryl Drugs?
Beryl Drugs major competitors are Decipher Labs, Unjha Formulations, Desh Rakshak Aushdh, iStreet Network, Venmax Drugs&Pharma, Colinz Laboratories, Hind Bio Science. Market Cap of Beryl Drugs is ₹12 Crs. While the median market cap of its peers are ₹12 Crs.
Is Beryl Drugs financially stable compared to its competitors?
Beryl Drugs seems to be financially stable compared to its competitors. The probability of it going bankrupt or facing a financial crunch seem to be lower than its immediate competitors.
Does Beryl Drugs pay decent dividends?
The company seems to be paying a very low dividend. Investors need to see where the company is allocating its profits. Beryl Drugs latest dividend payout ratio is 0% and 3yr average dividend payout ratio is 0%
How has Beryl Drugs allocated its funds?
Companies resources are allocated to majorly productive assets like Plant & Machinery and unproductive assets like Inventory, Accounts Receivable
How strong is Beryl Drugs balance sheet?
Balance sheet of Beryl Drugs is strong. It shouldn't have solvency or liquidity issues.
Is the profitablity of Beryl Drugs improving?
The profit is oscillating. The profit of Beryl Drugs is ₹0.77 Crs for Mar 2024, ₹0.77 Crs for Mar 2023 and -₹0.66 Crs for Mar 2022
Is the debt of Beryl Drugs increasing or decreasing?
Yes, The debt of Beryl Drugs is increasing. Latest debt of Beryl Drugs is ₹4.75 Crs as of Mar-24. This is greater than Mar-23 when it was ₹3.57 Crs.
Is Beryl Drugs stock expensive?
Beryl Drugs is expensive when considering the PE ratio, however latest EV/EBIDTA is < 3 yr avg EV/EBIDTA. Latest PE of Beryl Drugs is 149, while 3 year average PE is 18.5. Also latest EV/EBITDA of Beryl Drugs is 7.78 while 3yr average is 8.58.
Has the share price of Beryl Drugs grown faster than its competition?
Beryl Drugs has given lower returns compared to its competitors. Beryl Drugs has grown at ~-5.62% over the last 10yrs while peers have grown at a median rate of 12.85%
Is the promoter bullish about Beryl Drugs?
Promoters stake in the company seems stable, and we need to go through filings and allocation of resources to gauge promoter bullishness. Latest quarter promoter holding in Beryl Drugs is 26.38% and last quarter promoter holding is 26.38%.
Are mutual funds buying/selling Beryl Drugs?
There is Insufficient data to gauge this.